ENFIERA - 100MG

DEFINES :

Enfiera 100 mg is an anticancer medicine which prevents the growth and spread of cancer cells in the body. Enfiera 100 mg Injectionwill help to prevent the Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for Enfiera 100 mg rheumatoid arthritis symptoms in adult treatment. Enfiera 100 mg Injection with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.

INDICATIONS

Enfiera 100mg and hyaluronidase human injection are given alone or combination with other drugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).

Enfiera 100mg injection combination with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also indicated for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen knowns as tumor necrosis factor (TNF) inhibitor. Enfiera 100mg is a type in a classification of drugs called monoclonal antibodies.

Enfiera 100mg is used to killing cancer cells to treat NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by inhibiting the activity of the immune system parts that can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.

PREGNANCY CATEGORY

Category C: In animal studies reproduction describes an adverse effect on the fetus. There is no adequate and well developed studies in humans, using in pregnant women benefits by warrant use of the drug.

 LACTATION

The drug excretion into human milk is unknown. Because the drug is a higher protein molecule and has no information is available.

Women should not breast feed during Enfiera 100mg treatment and till12 months following last dose.

DOSAGE :

Enfiera injection is usually used to administrate only via intravenous infusion not by IV push or bolus.

Before Each Infusion the Drug Is Premediate :

First infusion:

Starting treatment rate of 50 mg/hr. is administer, in not showing infusion toxicity, rate raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

Successive infusion:

initial at rate of 100 mg/hr., in not showing infusion toxicity, rate raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

While combination with CHOP chemotherapy the injection Enfiera has not been given. Hence Premedication with corticosteroids must be considered.

Low grade or follicular non-Hodgkin’s lymphoma:

The drug Dose is 375 mg/m2 as an IV infusion.

Once weeks for 4 or 8 doses administrated for Relapsed treatment

Once weekly for 4 doses administrated for Retreatment for relapsed.

Previously untreated:

administer on day 1 of each cycle of chemotherapy, up to 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Enfiera 100mg in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent.

Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – progression (following CVP chemotherapy completion 6 – 8 cycles):

On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse Large B- cell NHL

Chronic Lymphocytic Leukemia :

Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

Component of Zevalin for treatment of NHL:

The dose 250 mg/m2 of Enfiera injection within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) Zevalin.

7–9 days before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin.

Rheumatoid Arthritis :

When combination of Enfiera injection with methotrexate is administrated.

Enfiera injection given as two doses of 100mg IV infusion 2 weeks separated.

When glucocorticoids administered as methylprednisolone 100mg IV

Subsequent course based on clinical evaluation must administer every 24 weeks, but not early than every 16 weeks.

Granulomatosis Polyangiitis And Microscopic Polyangiitis

Enfiera injection administer Dose of 375 mg/m2 IV infusion weekly once for 4 weeks.

When Glucocorticoids given with methylprednisolone by dose of 1000 mg IV/ day for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vacuities This drug should initiate within 14 days before or with the starting of Enfiera injection and may continue during and after the 4-week course with treatment of Enfiera injection drug.

Safety and not established for subsequent infusion.

Enfiera 100 mg

ADMINISTRTION :

Take an amount Enfiera injection is administer and diluted to final concentration of 1 mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Gently Invert the bag and mix the solution. Discard unused drug left in vial.

OVERDOSAGE:

If over dose occurs seek immediately to the emergency department or poison control help line. Please consult the doctor for further clarification.

PHARMACOKINETICS

Absorption:

Not available

Distribution:

volume of distribution is 3.1 L There is no human plasma level

Metabolism:

Enfiera 100mg metabolized by human antimurine antibody production.

Elimination :

not available The drug elimination of half-life of NHL is 22 days and for RA is 18.0 days, GPA and microscopic polyangiitis is 23 days.

MECHANISM OF ACTION

Enfiera 100mg is a type of class called as monoclonal antibody. A new type of "targeted" cancer treatment and an integral part of the body's immune system. Naturally the body fused to antibodies in along with an antigen which has entered the body and attack the antigen for destruction by the immune system.

Monoclonal antibiotics which only targeted by an essential cell only, they may cause less toxicity to healthy cell and it is prescribed treatment given only for cancers in which antigens (and the respective antibodies) have been already identified.

Enfiera injection works by linking to the CD20 antigen on normal and malignant B-cells. Hence natural immune security of body are initiated to attach and kill the marked B-cells. Young cells (stem cells) in the bone marrow which will develop into the various cell types and do not have the CD20 antigen. After treatment CD20 antigen allows healthy B-cells to multiply.

PRECAUTIONS :

Allergic condition against Enfiera 100mg or any other medication inform your doctor. Information about past medical history used which include in prescription, non-prescription, vitamins &supplements, nutritional products just inform the doctor.

While using Enfiera 100mg do not take any vaccination or immunization without taking advice from doctors.

Avoid use of Enfiera 100mg if you are pregnant. It will harm the baby unborn, while using Enfiera 100mguse correct birth control to prevent pregnancy and for at least 2 weeks after your treatment ends. Enfiera 100mgmay affect the ability to have children in women. Inform your doctor if you planning to pregnant.

It is unknown whether Enfiera 100mg passes into breast milk, avoid breast-feed while on Enfiera 100mgtreatment.

STORAGE

Store the drug at 2℃ – 3℃

Keep away from the childerns

Use the drug before expiry date

Protected from direct sunlight and Do not freeze or shake.

Discard the unused drug by asking the advice from doctor or pharmacist.

DRUG INTERACTION

Enfiera 100mg drug interaction has limited data is available at present.
Interaction with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients. Enfiera combination with methotrexate had no effects in pharmacokinetics.

CONTRAINDICATION

Hypersensitivity or murine proteins.
Active severe infections in rheumatoid arthritis
Uncontrolled cardiac disease.

MISSED DOSE

If a dose missed then have the drug soon you remembered, if next dose time reach then leave the missed dose and follow the normal schedule.
Do not have 2 doses at a same time. Please consult with doctor for further details.

SIDE EFFECTS

Common effects: fever and chills (flu lik symptoms)
Less common side effects: Weakness; nausea ; headache; cough ; dyspnea ; pharyngitis.

 

for more information please click this link below - Enfiera 100 mg , Enfiera 100 mg Injection

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals

PIRFENEX (PERFENIDONE) applepharmaceutical

PIRFENEX

DESCRIPCIÓN

Tablet Pirfenex es un fármaco eficaz, pero causa algunas afecciones potencialmente mortales. pirfenex precio Causa una estructura cromosómica anormal en pacientes que reciben Tablet Pirfenex; exposición

a la luz en pruebas de genotoxicidad. El paciente debe tener conocimiento sobre el potencial del medicamento Pirfenex

que causa carcinogénesis en la piel expuesta a la luz. La tableta Pirfenex se debe prescribir bajo la supervisión de

médico que está familiarizado con la terapia idiopática de fibrosis pulmonar. Tablet Pirfenex es un agente antifibrótico

involucrado en el tratamiento de la fibrosis pulmonar idiopática (enfermedad pulmonar).




INDICACIÓN




La tableta Pirfenex se usa principalmente en la condición de fibrosis pulmonar idiopática (FPI).




FARMACOLÓGICO




Pirfenex, el mecanismo de acción de la droga no está completamente establecido. Tablet Pirfenex es un

eficaz agente antifibrótico y antiinflamatorio. La actividad antifibrótica de Pirfenex se toma principalmente

en consideración. Pirfenex, se lleva a cabo la cantidad de terapia basada en células. Conduce a reducir la proliferación de fibroblastos,

prohíbe la producción acelerada de colágeno TGF-β y disminuye la síntesis de mediadores fibrogénicos como TGF-β (transformante

factor de crecimiento). Pirfenex tiene actividad para reducir la producción de mediadores inflamatorios como TNF-α (factor de necrosis tumoral) e IL-1β (interleucina 1 beta).







DOSIFICACIÓN




La dosis recomendada de tableta Pirfenex en adolescentes es de 200 mg durante tres veces al día (TID), 600 mg / día.

Dependiendo de la gravedad de la afección (IPF), la dosis puede ajustarse hasta 1800 mg / día. Dosis de la

tableta Pirfenex dependiendo del síntoma. Inicialmente, el paciente comienza con 200 mg de TID, después de 2 semanas, la dosis puede aumentar gradualmente a 600 mg a la vez (1800 mg / día).







Ajuste de dosis y otras consideraciones para un uso seguro:







Eventos gastrointestinales:

MABTAS RA - 500MG Applepharmaceutical

MABTAS RA - 500MG  Applepharmaceutical

DESCRIPTION :

Mabtas RA 500mg  is an anticancer medicine which prevents the growth and spread of cancer cells in the body.
Mabtas RA 500mg will help to prevent the Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for rheumatoid arthritis symptoms in adult treatment.
Mabtas RA 500mg inj  with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.




INDICATIONS :

Mabtas RA 500mg inj  and hyaluronidase human injection are given alone or combination with otherdrugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).
Mabtas RA 500mg inj  injection combination with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also indicated for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen knowns as tumor necrosis factor (TNF) inhibitor. Mabtas RA 500mg is a type in a classification of drugs called monoclonal antibodies.
Mabtas RA 500mg is used to killing cancer cells to treat NHL , CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by inhibiting the activity of the immune system parts that can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.



DOSAGE :
Mabtas RA injection is usually used to administrate only via intravenous infusion not by IV push or bolus.
Before Each Infusion the Drug Is Premediate :
First infusion:
Starting treatment rate of 50 mg/hr. is administer, in not showing infusion toxicity, rate raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

Successive infusion:  

initial at rate of 100 mg/hr., in not showing infusion toxicity, rate raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
While combination with CHOP chemotherapy the injection Mabtas RA has not been given. Hence Premedication with corticosteroids must be considered.

Low grade or follicular non-Hodgkin’s lymphoma:

The drug Dose is 375 mg/m2 as an IV infusion.

Once weeks for 4 or 8 doses administrated for Relapsed treatment

Once weekly for 4 doses administrated for Retreatment for relapsed.

Mabtas RA 500mg inj

Previously untreated:

administer on day 1 of each cycle of chemotherapy, up to 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas RA 500mg in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent.

Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – progression (following CVP chemotherapy completion 6 – 8 cycles):

On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse Large B- cell NHL

Chronic Lymphocytic Leukemia :

Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

Component of Zevalin for treatment of NHL:

The dose 250 mg/m2 of Mabtas RA injection within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) Zevalin.

7–9 days before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin.




Rheumatoid Arthritis:

When combination of Mabtas RA injection with methotrexate is administrated.

Mabtas RAinjection given as two doses of 100mg IV infusion 2 weeks separated.

When glucocorticoids administered as methylprednisolone 100mg IV

Subsequent course based on clinical evaluation must administer every 24 weeks, but not early than every 16 weeks.

Granulomatosis Polyangiitis And Microscopic Polyangiitis :

Mabtas RA injection administer Dose of 375 mg/m2 IV infusion weekly once for 4 weeks.

When Glucocorticoids given with methylprednisolone by dose of 1000 mg IV/ day for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vacuities This drug should initiate within 14 days before or with the starting of Mabtas RAinjection and may continue during and after the 4-week course with treatment of Mabtas RAinjection drug.

Safety and not established for subsequent infusion.

ADMINISTRTION :

Take an amount Mabtas RAinjection is administer and diluted to final concentration of 1 mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Gently Invert the bag and mix the solution. Discard unused drug left in vial.

OVERDOSAGE:

If over dose occurs seek immediately to the emergency department or poison control help line.

please consult the doctor for further clarification.







DRUG INTERACTION

Mabtas RA 500mg  drug interaction has limited data is available at present.

Interaction with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients.

Mabtas RA combination with methotrexate had no effects in pharmacokinetics.




CONTRAINDICATION

Hypersensitivity or murine proteins.

Active severe infections in rheumatoid arthritis

Uncontrolled cardiac disease.




MISSED DOSE

If a dose missed then have the drug soon you remembered, if next dose time reach then leave the missed dose and follow the normal schedule.

Do not have 2 doses at a same time. Please consult with doctor for further details.




SIDE EFFECTS

Common effects: fever and chills (flu lik symptoms)

Less common side effects: Weakness; nausea ; headache; cough ; dyspnea ; pharyngitis.

for more information : Mabtas RA 500mg,Mabtas RA 500mg inj

Phone :+91-9987711567Email :

applepharmaceutical@gmail.com

Email :

info@myapplepharma.com

0091-9987711567

VIVITRA - 150MG Applepharmaceutical

DESCRIPTION :

vivitra 150 mg is a group of medicines which belongs to antineoplastic medication. vivitra 150 mg injection is a chemotherapy drug. It is recommended that Vivitra 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.



USES :

The injection vivitra 150 mg is used alone or combined with other medicine for the treatment in patients who suffer . vivitra 150 mg injection from metastatic breast cancer.

The drug also indicated with a combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.



WORK AS

vivitra 150 mg Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.

Vivitra acts by adhering itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Vivitra can slow or inhibit the growth of breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.



DOSAGE :

The injection vivitra 150 mg should not mix with other drugs and do not administer as an intravenous push or bolus.

Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine

Adjuvant treatment, breast cancer:

The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:

During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:

Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV (intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Vivitra dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.

The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens: For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg

Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.

Adjuvant treatment stretching beyond one year is not recommended.

Metastatic Treatment, Breast Cancer:

Vivitra administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.

Metastatic Gastric Cancer:

Vivitra administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.



PRECAUTION :

Embryo fetal damage

Vivitra 150mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment




Cardiomyopathy

Patient getting Vivitra 150mg injection have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuing.

vivitra 150 mg injection

Pulmonary toxicity

Some serious fatal cases of pulmonary toxicity occur during Vivitra 150mg treatment.




Infusion reactions

During Vivitra 150mg treatment some life-threatening infusion reactions are produced.

In serious infusion reactions, Stop the Vivitra 150mg treatment permanently.

Patient should be treated with premedication before starting the infusion to overcome the such problem, During Vivitra 150mg treatment. Use with Caution.




Therapy induced neutropenia

Higher incidence of neutropenia occurs during Vivitra 150mg treatment.




DRUG SUMMARY
Probably no contraindicated occurs.
The patients are contraindicated to the component present in the Vivitra 150mg, Hence Hypersensitivity reactions are occurring.


STORAGE
Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Vivitra 150mg diluted bag at 2℃ to 8℃ for 24 hours.


MISSED DOSE
The drug Missing vivitra 150 mg injection doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.


SIDE EFFECTS :
Common side effects:
Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain


Serious side effects:
Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals

ZELGOR - 500MG (Applepharmaceutical)

ZELGOR - 500MG  (Applepharmaceutical)

Abiraterone is sold under brand name Zelgor 500mg ,( zelgor 500mg price in india ) belongs to type of anti-cancer medication that will act by a decline the androgen production in the body.
Androgen is a male hormone that can maintain the tumor cell in prostate glands.
This drug is given by co-administration with prednisolone, a steroid which reduces the liability of side effects produced by Abiraterone.

DOSAGE

The prescribed dose of  zelgor 500mg price in indiais initial as 4 tablets given orally once daily.
The drug Zelgor administrated combination with 5mg prednisolone twice daily in empty stomach.
• Zelgor 500mg Tablets given on an empty stomach.
• Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Zelgor Tablets is taken. • Swallowed whole with water. • Chew the tablets or Do not crush

Zelgor 500mg

MECHANISM OF ACTION :

Androgens are balance the production of malignant in prostate.

Zelgor 500mg belongs to anti androgen drugs, that causes to suppress the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is involving in androgen conglomerate.

Reduce the serum testosterone level.

Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Zelgor 500mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine

Half-life of tablet Zelgor 500mg is 12 ± 5 hours.

for more information please click this link below -Zelgor 500mg , zelgor 500mg price in india .

HERMAB - 150MG (Applepharmaceutical)

HERMAB - 150MG (Applepharmaceutical)

DESCRIPTION :

hermab 150mg  is a group of medicines which belongs to anti neoplastic medication.Hermab 150 mg injection is a chemotherapy drug. It is recommended that hermab 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

USES
The injection hermab 150mg  is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

WORK AS

Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.

hermab 150mg  acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals,hermab 150mg  can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting hermab 150mg  receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.

DOSAGE :

The injection Hermab should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant treatment, breast cancer:
The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:
During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV(intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Hermab dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.
The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
Hermab administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.

PRECAUTION :

DRUG INTERACTION

In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Hermab 150mg treatment.
Hermab 150mg interaction with anthracycline after ending of Hermab 150mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.

CONTRAINDICATION

Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hermab 150mg, Hence Hypersensitivity reactions are occurring.

STORAGE

Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hermab 150mg diluted bag at 2℃ to 8℃ for 24 hours.

MISSED DOSE :

The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.

hermab 150mg

SIDE EFFECTS :

Common side effects:
Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain

Serious side effects:

Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing


for more information please click this link below - Hermab 150mg , Hermab 150 mg injection

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals

SORAFENAT 200MG - Applepharma

描述

索拉芬特属于蛋白激酶抑制剂的类型，索拉非尼 索拉芬特被研究作为合成化合物靶向信号反应生长和血管生成。Sorafenat,

Sorafenat, 还通过阻断肿瘤血管生成来抑制VEGFR-2 索拉非尼 / PDGFR-β信号传导力。索拉非尼

Sorafenat是一种处方药，在医学肿瘤学家的指导下使用。索拉非尼
Sorafenat 处方信息

索拉芬特适用于治疗转移性肾细胞癌患者印度版索拉非尼多少钱索拉非尼吃了真能好吗

索拉芬特适用于治疗转移性肝细胞癌患者。索拉非尼

索拉芬特适用于甲状腺癌患者的治疗。
Sorafenat 机制

索拉非尼与多种细胞内（CRAF，BRAF和突变BRAF）和细胞表面激酶（KIT，FLT-3，VEGFR-2，VEGFR-3和PDGFR-β）结合。认为各种这些激酶包括在血管生​​成中，因此索拉非尼减少了流向肿瘤的血流量。索拉非尼特异性针对Raf / Mek / Erk途径。通过禁止这些激酶，禁止含有细胞增殖和血管生成的基因转录。
吸收

口服生物利用度为38％至49％。索拉非尼

索拉芬特的高血浆浓度时间为3小时。索拉非尼
分配

索拉非尼主要与人血浆蛋白结合，范围为99.5％
代谢

除了由UGT1A9介导的葡糖醛酸化外，索拉非尼还经历由CYP3A4介导的氧化代谢。
排泄

索拉芬特的排泄通过尿液，粪便和胆汁排泄也发生。印度版索拉非尼多少钱索拉非尼吃了真能好吗

索拉非尼的未改变形式是大约51％应该在粪便中回收而不是在尿液中，也会发生胆汁排泄。

Sorafenat, 的半衰期相对为25至48小时。Sorafenat,
剂量方案 Sorafenat 平板电脑

在HCC，RCC或TC条件：

索拉芬特的常用处方剂量为400mg片剂（200mg×2片），应每日服用两次。
HCC和RCC的剂量变化

如果需要减少剂量，Sorafenat 则应在HCC和RCC中改变剂量。剂量应减少至400mg单剂量。如果需要进一步减量，则在替代日提供400mg单剂量。
与HCC相关的皮肤病毒性剂量变化Sorafenat,

1级毒性：延长索拉芬特疗法并提供局部治疗以缓解症状。

2级毒性：Sorafenat 延长索拉芬特疗法并提供局部治疗以缓解症状。如果持续发生，停止索拉芬特治疗。

3级毒性：停止索拉芬特治疗，如果需要，剂量应每天减少两次，改为单剂量。
甲状腺癌的剂量改变

首次减少剂量：应推荐600毫克Sorafenat,

第二次剂量减少：每天两次服用400毫克索拉芬特

第三剂量减少：200mg索拉芬特应作为单剂量处方。
Sorafenat,造成副作用
最常见的副作用
手足皮肤反应
肌肉骨骼疾病 索拉非尼
体重减轻
增加淀粉酶和脂肪酶
腹泻
脱发
感染
上市后不良影响 索拉非尼
骨坏死
间质性肺病
毛囊炎
白细胞减少症Sorafenat
中性粒细胞减少
贫血
Stevens Johnson综合症
血管性水肿
甲状腺功能减退症 印度版索拉非尼多少钱索拉非尼吃了真能好吗
低钙血症
低钾血症
低钠血症
萧条
周围感觉神经病变
横纹肌溶解症
血小板减少
耳鸣
充血性心力衰竭
流鼻涕
发音困难
胃食管反流Sorafenat,
Sorafenat,药物 - 药物相互作用.

Sorafenat

同时施用Sorafenat 与抗生素如新霉素导致索拉非尼的AUC耗尽。

索拉芬特的溶解度取决于pH，如果pH增加导致溶解度降低。

Sorafenat 片剂与咪达唑仑，右美沙芬或奥美拉唑同时使用时，不会导致这些药物全身暴露。

索拉芬特与其他抗肿瘤药物共同给药;

紫杉醇或卡铂：引起索拉非尼暴露的升高

卡培他滨：增加卡培他滨的暴露。

多柔比星/伊立替康：阿霉素和伊立替康的AUC升高Sorafenat

与新霉素组合：对索拉非尼的肠肝循环进行干预，导致索拉非尼暴露的消耗。

索拉芬特片与强效CYP3A4抑制剂同时使用，如酮康唑，索拉非尼的AUC无变化。
索拉芬特的禁忌症

在患有鳞状细胞肺癌的患者中，Sorafenat 与卡铂和紫杉醇联合使用是禁忌的。

如果患者禁忌Sorafenat 片剂，则会发生一些过敏反应。索拉非尼
预防

索拉芬特片治疗期间出现一些不良反应;

停止Sorafenat 的治疗 索拉非尼

索拉芬特与华法林的组合导致INR水平升高。为避免此问题，经常监测患者出血（凝血酶原时间）。

索拉芬特片应在手术过程中推迟，以防止伤口并发症。

索拉芬特与卡铂/紫杉醇联合吉西他滨/顺铂治疗鳞癌的死亡率升高：

对于患有鳞状细胞肺癌的患者，这种组合是禁忌的。印度版索拉非尼多少钱索拉非尼吃了真能好吗

索拉芬特导致QT间期延长;对有心脏病的患者避免这种疗法。

在Sorafenat治疗期间，转氨酶升高导致肝损伤并导致肝功能衰竭。

索拉芬特片剂会对胎儿造成伤害 印度版索拉非尼多少钱索拉非尼吃了真能好吗

应经常监测TSH水平并调整甲状腺替代。

经常监测血压并为此病情提供抗高血压药物。
怀孕和哺乳期
怀孕

索拉芬特片的妊娠类别：D印度版索拉非尼多少钱索拉非尼吃了真能好吗

在怀孕条件下不应推荐索拉芬特片

不建议母乳喂养

储存和处理 印度版索拉非尼多少钱索拉非尼吃了真能好吗

Sorafenat 平板电脑存储在 25oC (77oF).

保护容器免受潮湿，高温和光照
错过剂量

如果患者错过服用索拉芬特的剂量，必须咨询医生并按照说明进行操作。或者应该跳过错过的剂量并遵循常规给药方案。Sorafenat,  索拉非尼 , 印度版索拉非尼多少钱索拉非尼吃了真能好吗

我们的 联系人

    +919987711567

     info@applepharma.cn  

      applepharmaceutical@gmail.com           

VIRADAY (TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ & EMTRICITABINE)DESCRIPCIÓN

DESCRIPCIÓN ;

Los comprimidos de Viraday contienen componentes activos que tienen fármacos ( viraday precio ) antirretrovirales conocidos como tenofovir disoproxil fumarato, efavirenz, emtricitabina. Viraday ( viraday precio ) es un producto aprobado por la FDA, que es activo contra la condición de infección por VIH 1. Los componentes que contienen ( viraday precio ) son; Efavirenz: inhibidor Viraday no nucleosídico de la transcriptasa inversa Emtricitabina: inhibidores Viraday de la nucleósido transcriptasa inversa Tenofovir DF: inhibidores de la Viraday nucleósido transcriptasa inversa.

INDICACIONES

La información de Viraday prescripción común de los comprimidos de Viraday se utiliza para tratar la infección por VIH-1 si se usa solo o en combinación con otros medicamentos antirretrovirales. Un uso de Viraday (buy viraday online ) es aplicable para adultos y pacientes pediátricos de aproximadamente 12 años de edad y mayores.buy viraday online ,

MECANISMO

Efavirenz
Efavirenz muestra un movimiento hostil al retroviral al reprimir el giro de la transcriptasa, buy viraday online , que es una proteína polimerasa de ADN polimerasa coordinada con ARN viral básica.

VIRADAY 

для получения дополнительной информации, пожалуйста, нажмите на эту ссылку ниже — Viraday , viraday precio ,buy viraday online ,

NAIVEX (Dolutegravir)

描述 : 

Naivex印度药 还反对复古病毒药物，包括Dolutegravir作为功能部分。Naivex 印度价格 不应该单独使用;它可能与其他敌对逆转录病毒的经营者合并，以更好地对抗HIV-1疾病。 Naivex 印度价格 并未治愈HIV-1疾病，Naivex印度药 但用于控制体内HIV的数量，并排除艾滋病毒感染艾滋病毒的严重疾病。

迹象 :

Naivex印度药 和广泛证明用于治疗HIV-1疾病，在体重35公斤的成年人和儿科患者中不完全。 Naivex在混合时是有利的;不是分区利用 Naivex印度药
药剂学类别

两者都对逆转录病毒处方有敌意Naivex：整合酶链交换抑制剂（Integrase是负责将HIV遗传物质交换到人类染色体中的蛋白质导致创造）
工作为

Naivex印度药 （Dolutegravir）含有与HIV病毒特性相矛盾的东西，这让我感到羞耻。 Naivex被称为Integrase抑制剂，它可以通过调整整合酶来降低HIV细胞变化，从而实现对侵袭性部位和封锁贸易步骤的阻断。病毒DNA混合使细胞停止这种交易程序对HIV细胞增量周期负责。这会阻碍病毒的发展 Naivex 印度价格

剂量




患者肌酐自由，尿蛋白，尿糖应偶尔观察。 Naivex印度药：由50毫克 Dolutegravir组成
Naivex的剂量推荐

两种产品的标准认可剂量是一片应该作为单一剂量口服。 Naivex印度药 应该在有或没有用餐的情况下服用。 Naivex应该有能力服用成人患者和体重不低于35公斤的儿科
药代动力学.

吸收：

Dolutegravir的最大血浆浓度时间为2至3小时。持续状态水平达到5天内 Naivex印度药

分配：

Dolutegravir主要与人血浆蛋白结合，为98.9％ Naivex印度药

代谢：

Dolutegravir的代谢是通过UGT1A1进行的 Naivex印度药，并有一些来自CYP3A的额外承诺。

排除方法：

Dolutegravir的终端半存在是14个小时。处理的重要过程是尿液和通过粪便的未改变的框架。
药物相互影响

Naivex与通过OCT2或MATE1（多非利特或二甲双胍）释放的药物结合，导致这些药物的血浆浓度延长。 Naivex与etravirine联合导致Dolutegravir血浆传播减少。 Naivex同时用于威胁分枝杆菌，对抗惊厥或草药产品，如st。约翰斯麦汁引起Dolutegravir血浆传播的耗竭。 Dolutegravir是UGT1A3，UGT1A9，BCRP和P-gp转运蛋白的底物。 Naivex加入处方，禁止这些合成化合物或转运蛋白引起，增加Dolutegravir的血浆浓度。Naivex 印度价格 片剂是非核苷类逆转录酶抑制剂的专家用途;导致利用Naivex联盟的影响。如果Naivex片剂与蛋白酶抑制剂固化导致Dolutegravir的血浆分配减少。
安全措施

过敏反应：

这可能是禁忌症的结果

由于药物相互作用而未出现病毒学应答：

Naivex印度药 的抗药性可能发生在使用其他药物的患者身上。

安全重组问题：

一些庇护性改变疾病发生在威胁复古病毒治疗的基本时期 Naivex 印度价格

安全重组问题：

一些庇护性改变疾病发生在威胁复古病毒治疗的基本时期 Naivex印度药

副作用 :

这种疗法会产生不良反应;肝毒性过敏反应免疫重建综合征

最常见的副作用如;失眠中性粒细胞升高脂肪酶增加焦虑抑郁肌酸激酶升高 Naivex 印度价格
儿科

在儿科患者的体重不低于35公斤，对复古病毒治疗的敌意是相关的。体重不足25公斤：Naivex 印度价格 的强度不应该评估。
失败的剂量

Naivex对逆转录病毒处方不友好，如果在治疗过程中发生遗漏测量，必须直接与治疗大师一起按照他们的建议指示服用。另一方面，应避免错过剂量并采取标准时间表。

哺乳期 :

在儿科患者的体重不低于35公斤 Naivex印度药，对复古病毒治疗的敌意是相关的。体重不足25公斤：Naivex 印度价格
存储

Naivex容器应保持在25℃，保护容器远离光线，潮湿和高温。

 欲了解更多信息，请点击以下链接  :      naivex 印度仿制 , Naivex印度药 , Naivex 印度价格 ,

TAFERO (ТЕНОФОВИР АЛАФЕНАМИД 25 МГ)

 TAFERO (ТЕНОФОВИР АЛАФЕНАМИД 25 МГ)

ОПИСАНИЕ :

Tafero25 мг  Тенофовир алафенамид является антигепацивирусным и антиретровирусным препаратом. Tafero25 мг  У пациентов с ВИЧ Tafero возможно комбинирование препаратов с эмтрицитабином, кобицистатом или дарунавиром. Tafero Сначала Tafero обладает антиретровирусным действием (ингибитор нуклеозидной обратной транскриптазы), Tafero теперь Tafero обладает антигепацивирусным свойством. Tafero

ОБЛАСТЬ ПРИМЕНЕНИЯ

Таблетка  Tafero25 мг Tafero может быть использована для снижения риска заражения. вирусная передача Tafero revisión

КАТЕГОРИЯ

Антиретровирусный препарат Tafero25 мг
Анти-гепацивирусный препарат

tafnat ТАБЛЕТКА

Обычная Tafero  дозировка таблетки Tafero : одну таблетку, содержащую 25 мг тенофовира алафенамида, следует принимать в виде разовой дозы. Таблетку Tafero следует вводить вместе с пищей. В диапазоне клиренса креатинина <15 мл / мин, Tafero не Tafero revisión  рекомендуется. При декомпенсированном циррозе печени: Tafero не следует принимать. Рекомендуется Перед началом терапии: Пациентам следует исследовать инфекцию ВИЧ-1 для рекомендации комбинации других антиретровирусных препаратов у ВИЧ-1-положительных пациентов. Tafero revisión

РАБОТАЕТ

Tafero revisión   -тенофовир алафенамид (TAF) TAF является пролекарством тенофовира (исходного лекарственного средства). Сначала TAF проникает в клетки печени, поскольку обладает проницаемостью для липофильных клеток. Tafero revisión   После попадания в клетки TAF подвергается гидролизу с использованием карбоксилэстеразы-1 и образуется в виде тенофовира. Tafero revisión   Тенофовир участвует во внутриклеточном метаболизме, который фосфорилируется в тенофовир трифосфат. Тенофовир трифосфат считается активным метаболитом, который обладает противовирусным Tafero revisión  свойством и интегрируется в вирусную ДНК ферментом обратной транскриптазы гепатита В и приводит к ингибированию вирусной продукции, что приводит к обрыву вирусной цепи.  Tafero.

Tafero

для получения дополнительной информации, пожалуйста, нажмите на эту ссылку ниже  - Tafero revisión ,        Tafero  25 мг таблетка  , таферо 25 мг таблетка, Tafero25 мг , Tafero цена в Индии